Bristol-Myers Squibb (NYSE:BMY – Get Free Report) posted its earnings results on Friday. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.67 by $0.40, RTT News reports. The company had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.75 earnings per share. Bristol-Myers Squibb updated its FY24 guidance to $0.60-0.90 EPS and its FY 2024 guidance to 0.600-0.900 EPS.
Bristol-Myers Squibb Trading Up 11.3 %
NYSE:BMY traded up $5.13 during mid-day trading on Friday, hitting $50.40. 36,625,950 shares of the company’s stock were exchanged, compared to its average volume of 15,918,454. The company has a 50 day simple moving average of $41.63 and a 200-day simple moving average of $46.83. The firm has a market capitalization of $102.17 billion, a P/E ratio of -15.75, a PEG ratio of 16.73 and a beta of 0.44. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.41. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.
Bristol-Myers Squibb Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 4.76%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.
Analyst Ratings Changes
View Our Latest Stock Analysis on BMY
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- Financial Services Stocks Investing
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.